One hundred consecutive isolated limb perfusions with TNF-α and melphalan in melanoma patients with multiple in-transit metastases

Annals of Surgery

Volumn 240, Issue 6, 2004, Pages 939-948

  Grünhagen, Dirk J ^a   Brunstein, Flavia ^a   Graveland, Wilfried J ^a   Van Geel, Albertus N ^a   De Wilt, Johannes H W ^a   Eggermont, Alexander M M ^a   Rinkes, Borel ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GAMMA INTERFERON; MELPHALAN; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; AMPUTATION; BLISTER; BLOOD TOXICITY; CANCER GROWTH; CANCER LOCALIZATION; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COMPARTMENT SYNDROME; CONFERENCE PAPER; DEATH; DISEASE SEVERITY; EDEMA; EPIDERMOLYSIS; ERYTHEMA; FEMALE; FUNCTIONAL DISEASE; HUMAN; HYPOTENSION; LEUKOPENIA; LIMB PERFUSION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; NEPHROTOXICITY; NEUROLOGIC DISEASE; PRIORITY JOURNAL; PROGNOSIS; RHABDOMYOLYSIS; SHOCK; TIME SERIES ANALYSIS; TISSUE INJURY; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, ALKYLATING; AXILLARY ARTERY; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; EXTREMITIES; FEMALE; FEMORAL ARTERY; HUMANS; ILIAC ARTERY; MALE; MELANOMA; MELPHALAN; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; SKIN NEOPLASMS; SURVIVAL RATE; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 10044239265     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.sla.0000146147.89667.ed     Document Type: Conference Paper

References (41)

1. Eggermont AM. Treatment of melanoma in-transit metastases confined to the limb. Cancer Surv. 1996;26:335-349.
2. Creech O Jr, Krementz ET, Ryan RF, Winblad JN. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg. 1958;148:616-32.
3. Benckhuijsen C, Kroon BB, van Geel AN, Wieberdink J. Regional perfusion treatment with melphalan for melanoma in a limb: an evaluation of drug kinetics. Eur J Surg Oncol. 1988;14:157-163.
4. Thompson JF, Gianoutsos MP. Isolated limb perfusion for melanoma: effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs. World J Surg. 1992;16:227-233.
5. Klaase JM, Kroon BB, Benckhuijsen C, et al. Results of regional isolation perfusion with cytostatics in patients with soft tissue tumors of the extremities. Cancer. 1989;64:616-621.
6. Lienard D, Ewalenko P, Delmotte JJ, et al. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol. 1992;10:52-60.
7. Eggermont AM, Schraffordt Koops H, Lienard D, et al. Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol. 1996;14:2653-2665.
8. Eggermont AM, Schraffordt Koops H, Klausner JM, et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg. 1996;224:756-765.
9. Lejeune F, Lienard D, Eggermont A, et al. Rationale for using TNF alpha and chemotherapy in regional therapy of melanoma. J Cell Biochem. 1994;56:52-61.
10. de Wilt JH, ten Hagen TL, de Boeck G, et al. Tumor necrosis factor alpha increases melphalan concentration in tumor tissue after isolated limb perfusion. Br J Cancer. 2000;82:1000-1003.
11. Smith J. Histopathology and Biological Behavior of Melanoma, Neoplasms of the Skin and Malignant Melanomas. Chicago: Year Book Medical Publishers; 1976.
12. Klaase JM, Kroon BB, van Geel AN, et al. Systemic leakage during isolated limb perfusion for melanoma. Br J Surg. 1993;80:1124-1126.
13. Wieberdink J, Benckhuysen C, Braat RP, et al. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol. 1982;18: 905-910.
14. WHO. WHO Handbook for Reporting Results of Cancer Treatment. Geneva: World Health Organisation; 1979.
15. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
16. Di Filippo F, Calabro A, Giannarelli D, et al. Prognostic variables in recurrent limb melanoma treated with hyperthermic antiblastic perfusion. Cancer. 1989;63:2551-2561.
17. Klaase JM, Kroon BB, van Geel AN, et al. Prognostic factors for tumor response and limb recurrence-free interval in patients with advanced melanoma of the limbs treated with regional isolated perfusion with melphalan. Surgery. 1994;115:39-45.
18. Lienard D, Eggermont AM, Koops HS, et al. Isolated limb perfusion with tumor necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study. Melanoma Res. 1999;9:491-502.
19. Vrouenraets BC, Hart GA, Eggermont AM, et al. Relation between limb toxicity and treatment outcomes after isolated limb perfusion for recurrent melanoma. J Am Coll Surg. 1999;188:522-530.
20. Zogakis TG, Bartlett DL, Libutti SK, et al. Factors affecting survival after complete response to isolated limb perfusion in patients with in-transit melanoma. Ann Surg Oncol. 2001;8:771-778.
21. Noorda EM, Vrouenraets BC, Nieweg OE, et al. Prognostic factors for survival after isolated limb perfusion for malignant melanoma. Eur J Surg Oncol. 2003;29:916-921.
22. Stam TC, Swaak AJ, de Vries MR, et al. Systemic toxicity and cytokine/ acute phase protein levels in patients after isolated limb perfusion with tumor necrosis factor-alpha complicated by high leakage. Ann Surg Oncol. 2000;7:268-275.
23. Lejeune FJ, Lienard D, Leyvraz S, Mirimanoff RO. Regional therapy of melanoma. Eur J Cancer. 1993;29A:606-612.
24. Vaglini M, Belli F, Ammatuna M, et al. Treatment of primary or relapsing limb cancer by isolation perfusion with high-dose alpha-tumor necrosis factor, gamma-interferon, and melphalan. Cancer. 1994;73: 483-492.
25. Fraker DL, Alexander HR, Andrich M, Rosenberg SA. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study. J Clin Oncol. 1996;14:479-489.
26. Soengas MS, Capodieci P, Polsky D, et al. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature. 2001;409:207-211.
27. Ivanov VN, Bhoumik A, Ronai Z. Death receptors and melanoma resistance to apoptosis. Oncogene. 2003;22:3152-3161.
28. Manusama ER, Nooijen PT, Stavast J, et al. Assessment of the role of neutrophils on the antitumor effect of TNFalpha in an in vivo isolated limb perfusion model in sarcoma-bearing brown Norway rats. J Surg Res. 1998;78:169-175.
29. Renard N, Lienard D, Lespagnard L, et al. Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumor necrosis factor alpha (rTNF alpha). Int J Cancer. 1994;57:656-663.
30. Nooijen PT, Eggermont AM, Schalkwijk L, et al. Complete response of melanoma-in-transit metastasis after isolated limb perfusion with tumor necrosis factor alpha and melphalan without massive tumor necrosis: a clinical and histopathological study of the delayed-type reaction pattern. Cancer Res. 1998;58:4880-4887.
31. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001;19:3622-3634.
32. de Wilt JH, Thompson JF. Is there a role for isolated limb perfusion with tumor necrosis factor in patients with melanoma? Ann Surg Oncol. 2004;11:119-121.
33. Fraker DL, Alexander HR, Ross M, et al. A phase III trial of isolated limb perfusion for extremity melanoma comparing melphalan alone versus melphalan plus tumor necrosis factor (TNF) plus interferon gamma (IFN). Ann Surg Oncol. 2002;9:S8.
34. Rossi CR, Foletto M, Mocellin S, et al. Hyperthermic isolated limb perfusion with low-dose tumor necrosis factor-alpha and melphalan for bulky in-transit melanoma metastases. Ann Surg Oncol. 2004;11: 173-177.
35. Bartlett DL, Ma G, Alexander HR, et al. Isolated limb reperfusion with tumor necrosis factor and melphalan in patients with extremity melanoma after failure of isolated limb perfusion with chemotherapeutics. Cancer. 1997;80:2084-2090.
36. Klop WM, Vrouenraets BC, van Geel BN, et al. Repeat isolated limb perfusion with melphalan for recurrent melanoma of the limbs. J Am Coll Surg. 1996;182:467-472.
37. Vrouenraets BC, Eggermont AM, Hart AA, et al. Regional toxicity after isolated limb perfusion with melphalan and tumor necrosis factor-alpha versus toxicity after melphalan alone. Eur J Surg Oncol. 2001;27: 390-395.
38. Vrouenraets BC, Klaase JM, Kroon BB, et al. Long-term morbidity after regional isolated perfusion with melphalan for melanoma of the limbs. The influence of acute regional toxic reactions. Arch Surg. 1995;130: 43-47.
39. Swaak AJ, Lienard D, Schraffordt Koops H, et al. Effects of recombinant tumor necrosis factor (rTNF-alpha) in cancer. Observations on the acute phase protein reaction and immunoglobulin synthesis after high dose recombinant TNF-alpha administration in isolated limb perfusions in cancer patients. Eur J Clin Invest. 1993;23:812-818.
40. Thom AK, Alexander HR, Andrich MP, et al. Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion with high-dose tumor necrosis factor, interferon gamma, and melphalan. J Clin Oncol. 1995;13:264-273.
41. Eggermont AM, de Wilt JH, ten Hagen TL. Current uses of isolated limb perfusion in the clinic and a model system for new strategies. Lancet Oncol. 2003;4:429-437.